The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose more than 3% in the afternoon. As of press release, it had risen 3.04% to HK$12.53, with a turnover of HK$206.32,200.

According to the news, on September 29, Keji Pharmaceutical-B announced that CT1190B, a general-purpose CAR-T cell product targeting CD19/CD20, completed the first patient infusion in a phase I registered clinical trial in China to treat patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who failed at least second-line standard treatment. IIT findings on CT1190B were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.